跳转至内容
Merck

SML2802

Sigma-Aldrich

ATR-101

≥98% (HPLC)

别名:

1[[1[4(Dimethylamino)phenyl]cyclopentyl]methyl]3[2,6di(propan2yl)phenyl]urea hydrochloride, ATR 101, ATR101, CI-984, N-[2,6-bis(1-Methylethyl)phenyl]-N-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea hydrochloride, Nevanimibe HCl, PD 132301 HCl, PD 132301-02, PD 132301-2, PD132301 HCl, PD132301-02, PD132301-2

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H39N3O·HCl
分子量:
458.08
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

InChI

1S/C27H39N3O.ClH/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6;/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31);1H

InChI 密鑰

SDOOGTHIDFZUNM-UHFFFAOYSA-N

生化/生理作用

ATR-101 (PD 132301-02; Nevanimibe HCl) is an orally active, potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT1, SOAT1) inhibtior (IC50 = 52 nM; intestinal microsome from cholesterol-fed rabbits) that reduces plasma cholesterol in both acute (by 77%; 50 mg/kg po.) and chronic (by 80%; 10 mg/kg po.) cholesterol-fed rat models. In addition, ATR-101 is reported to exhibit therapeutic efficacy against adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH), and Cushing′s syndrome (CS).

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Yunhui Cheng et al.
Endocrine-related cancer, 23(4), 1-19 (2016-02-05)
Adrenocortical carcinoma (ACC) generally has poor prognosis. Existing treatments provide limited benefit for most patients with locally advanced or metastatic tumors. We investigated the mechanisms for the cytotoxicity, xenograft suppression, and adrenalytic activity of ATR-101 (PD132301-02), a prospective agent for
M A Dominick et al.
Fundamental and applied toxicology : official journal of the Society of Toxicology, 20(2), 217-224 (1993-02-01)
PD 132301-2 is a substituted urea hypolipidemic and antiatherosclerotic agent that is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). To determine its subacute toxicity, PD 132301-2 was administered orally to beagle dogs at 0, 6, 12, 25, 50, 200, 400
J F Reindel et al.
Toxicologic pathology, 22(5), 510-518 (1994-09-01)
PD 132301-2, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, was administered orally to cynomolgus monkeys for 2 wk at doses of 25, 50, 100, and 200 mg/kg to assess potential subacute toxicity. Sporadic episodes of soft feces and diarrhea increased in
M A Dominick et al.
Toxicologic pathology, 21(1), 54-62 (1993-01-01)
PD 132301-2, a novel inhibitor of acyl-CoA:cholesterol acyltransferase, is adrenotoxic to several laboratory animal species. Morphogenesis of a zona fasciculata-specific cytotoxicity was evaluated in male Hartley guinea pigs administered 100 mg/kg of PD 132301-2 for up to 7 days. Reversibility
G H Wolfgang et al.
Life sciences, 56(13), 1089-1093 (1995-02-17)
To assess whether previously reported ultrastructural alterations of adrenocortical mitochondria induced by the acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor PD 132301-2 are accompanied by functional deficits in tissue energy stores, phosphorylated adenine nucleotide levels in guinea pig adrenal cortex were quantitated. Adrenals

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门